Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Source: SeekingAlpha
2026-03-03 12:05:28 ET
Ascendis Pharma ( ASND ) announced the FDA approval of Yuviwel (navepegritide/TransCon CNP) for the treatment of children with achondroplasia. The regulatory decision comes despite the legal challenges by competitor BioMarin ( BMRN )....
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
11.99% G/L:
$73.43 Last:
2,577,187 Volume:
$66.12 Open:
BBIO Latest News
March 04, 2026 07:30:00 am
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
February 24, 2026 04:01:00 pm
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
